Diurnal Group PLC Block Admission Application (4038C)
11 Octobre 2022 - 8:00AM
UK Regulatory
TIDMDNL
RNS Number : 4038C
Diurnal Group PLC
11 October 2022
Diurnal Group PLC
("Diurnal" or the "Company")
Block Admission Application
Diurnal Group PLC (AIM: DNL), the specialty pharmaceutical
company targeting patient needs in chronic endocrine (hormonal)
diseases, announces that an application has been made to the London
Stock Exchange for a block admission of 1,171,533 ordinary shares
of 5 pence each ("Ordinary Shares") to be admitted to trading on
AIM ("Block Admission").
The Block Admission relates to Ordinary Shares that will be
issued from time to time in connection with the Company's share
plans, including satisfying outstanding options already issued
under the Diurnal Share Option Scheme 2015, options issued on the
same terms as those issued under the Company's long term incentive
plan or share options issued in September 2015. All Ordinary Shares
issued pursuant to the Block Admission above will rank pari passu
with the existing Ordinary Shares.
It is expected that the Block Admission will become effective on
or around 13 October 2022. The Company will make six-monthly
announcements of the utilisation of the block admission, in line
with its obligations under AIM Rule 29.
For further information, please contact:
Diurnal Group PLC 020 3727 1000
Richard Bungay, Interim Chief Executive Officer
FTI Consulting (Media and Investor Relations) 020 3727 1000
Simon Conway
Victoria Foster Mitchell
Alex Davis
Panmure Gordon (Nomad and Broker) 02 0 7886 2500
Freddy Crossley
Emma Earl
Rupert Dearden
About Diurnal
Diurnal Group plc is a European, UK-headquartered, specialty
pharmaceutical company dedicated to developing hormone therapeutics
to aid lifelong treatment for rare and chronic endocrine
conditions, including congenital adrenal hyperplasia, adrenal
insufficiency, hypogonadism and hypothyroidism. Its expertise and
innovative research activities focus on circadian-based
endocrinology to yield novel product candidates in the rare and
chronic endocrine disease arena.
For further information please visit: www.diurnal.co.uk
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
ALSFLFFDIRLILIF
(END) Dow Jones Newswires
October 11, 2022 02:00 ET (06:00 GMT)
Diurnal (LSE:DNL)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Diurnal (LSE:DNL)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024